In an industry defined by capital constraints and scientific uncertainty, small- to mid-sized biotech firms are increasingly embracing a bold new financial strategy: building strategic digital asset treasuries. It’s a move that signals not just a shift in portfolio management, but a deeper evolution in how these companies raise capital, manage liquidity, and insulate themselves […]

The post Digital Asset Treasuries Could Be the Lifeline Lower-Middle Market Biotech Firms Need first appeared on The UCW Newswire : Blockchain and Crypto News.